Alzheimer's disease (AD) is a progressive degenerative neurological disorder affecting nearly one in nine elderly people in the United States. Population studies have shown that an inheritance of the apolipoprotein E (APOE) variant APOE4 allele increases the risk of developing AD, whereas APOE2 homozygotes are protected from late-onset AD. It was hypothesized that expression of the “protective” APOE2 variant by genetic modification of the central nervous system (CNS) of APOE4 homozygotes could reverse or prevent progressive neurologic damage. To assess the CNS distribution and safety of APOE2 gene therapy for AD in a large-animal model, intraparenchymal, intracisternal, and intraventricular routes of delivery to the CNS of nonhuman primates of AAVrh.10hAPOE2-HA, an AAVrh.10 serotype coding for an HA-tagged human APOE2 cDNA sequence, were evaluated. To evaluate the route of delivery that achieves the widest extent of APOE2 expression in the CNS, the expression of APOE2 in the CNS was evaluated 2 months following vector administration for APOE2 DNA, mRNA, and protein. Finally, using conventional toxicology assays, the safety of the best route of delivery was assessed. The data demonstrated that while all three routes are capable of mediating ApoE2 expression in AD relevant regions, intracisternal delivery of AAVrh.10hAPOE2-HA safely mediated wide distribution of ApoE2 with the least invasive surgical intervention, thus providing the optimal strategy to deliver vector-mediated human APOE2 to the CNS.
Get full access to this article
View all access options for this article.
References
1.
HebertLE, WeuveJ, ScherrPA, et al.Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology, 2013; 80:1778–1783.
CummingsJL, MorstorfT, ZhongK. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther, 2014; 6:37.
4.
HungSY, FuWM. Drug candidates in clinical trials for Alzheimer's disease. J Biomed Sci, 2017; 24:47.
5.
SaundersAM, StrittmatterWJ, SchmechelD, et al.Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology, 1993; 43:1467–1472.
6.
GeninE, HannequinD, WallonD, et al.APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry, 2011; 16:903–907.
7.
MahleyRW. Apolipoprotein E: remarkable protein sheds light on cardiovascular and neurological diseases. Clin Chem, 2017; 63:14–20.
8.
ZannisVI, BreslowJL. Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification. Biochemistry, 1981; 20:1033–1041.
9.
CorderEH, SaundersAM, StrittmatterWJ, et al.Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science, 1993; 261:921–923.
10.
SandoSB, MelquistS, CannonA, et al.APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer's disease; a case control study from central Norway. BMC Neurol, 2008; 8:9.
11.
FarrerLA, CupplesLA, HainesJL, et al.Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA, 1997; 278:1349–1356.
12.
Conejero-GoldbergC, GomarJJ, Bobes-BascaranT, et al.APOE2 enhances neuroprotection against Alzheimer's disease through multiple molecular mechanisms. Mol Psychiatry, 2014; 19:1243–1250.
13.
NagyZ, EsiriMM, JobstKA, et al.Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience, 1995; 69:757–761.
14.
CorderEH, SaundersAM, RischNJ, et al.Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet, 1994; 7:180–184.
15.
LiuCC, LiuCC, KanekiyoT, et al.Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol, 2013; 9:106–118.
16.
EllisRJ, OlichneyJM, ThalLJ, et al.Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology, 1996; 46:1592–1596.
17.
KokE, HaikonenS, LuotoT, et al.Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol, 2009; 65:650–657.
18.
BalesKR, LiuF, WuS, et al.Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J Neurosci, 2009; 29:6771–6779.
ReimanEM, ChenK, LiuX, et al.Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A, 2009; 106:6820–6825.
21.
SchmechelDE, SaundersAM, StrittmatterWJ, et al.Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A, 1993; 90:9649–9653.
22.
AlvesS, FolR, CartierN. Gene therapy strategies for Alzheimer's disease: an overview. Hum Gene Ther, 2016; 27:100–107.
23.
DodartJC, MarrRA, KoistinahoM, et al.Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A, 2005; 102:1211–1216.
24.
HudryE, DashkoffJ, RoeAD, et al.Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci Transl Med, 2013; 5:212ra161.
25.
KaplittM, GourasGK, MakimuraH, et al.Apolipoprotein E, A beta-amyloid, and the molecular pathology of Alzheimer's disease. Therapeutic implications. Ann New York Acad Sci, 1996; 802:42–49.
26.
ZhaoL, GottesdienerAJ, ParmarM, et al.Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models. Neurobiol Aging, 2016; 44:159–172.
27.
PiguetF, SondhiD, PiraudM, et al.Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice. Hum Gene Ther, 2012; 23:903–914.
28.
SondhiD, JohnsonL, PurpuraK, et al.Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis. Hum Gene Ther Methods, 2012; 23:324–335.
29.
SondhiD, PetersonDA, GiannarisEL, et al.AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL. Gene Ther, 2005; 12:1618–1632.
30.
RafiMA, RaoHZ, LuziP, et al.Extended normal life after AAVrh10-mediated gene therapy in the mouse model of Krabbe disease. Mol Ther, 2012; 20:2031–2042.
31.
RosenbergJB, SondhiD, RubinDG, et al.Comparative efficacy and safety of multiple routes of direct CNS administration of adeno-associated virus gene transfer vector serotype rh.10 expressing the human arylsulfatase A cDNA to nonhuman primates. Hum Gene Ther Clin Dev, 2014; 25:164–177.
32.
SondhiD, HackettNR, PetersonDA, et al.Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Mol Ther, 2007; 15:481–491.
33.
SondhiD, PetersonDA, EdelsteinAM, et al.Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis. Exp Neurol, 2008; 213:18–27.
34.
ZerahM, PiguetF, ColleMA, et al.Intracerebral gene therapy using AAVrh.10-hARSA recombinant vector to treat patients with early-onset forms of metachromatic leukodystrophy: preclinical feasibility and safety assessments in nonhuman primates. Hum Gene Ther Clin Dev, 2015; 26:113–124.
35.
SondhiD, RosenbergJB, DeBP, et al.Long-term toxicology evaluation of AAVrh.10hARSA administration to the CNS of nonhuman primates to treat metachromatic leukodystrophy. Mol Ther, 2016; 24:S146.
36.
DeBP, HeguyA, HackettNR, et al.High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses. Mol Ther, 2006; 13:67–76.
37.
HackettNR, RedmondDE, SondhiD, et al.Safety of direct administration of AAV2(CU)hCLN2, a candidate treatment for the central nervous system manifestations of late infantile neuronal ceroid lipofuscinosis, to the brain of rats and nonhuman primates. Hum Gene Ther, 2005; 16:1484–1503.
38.
LiddieS, GoodyRJ, VallesR, et al.Clinical chemistry and hematology values in a Caribbean population of African green monkeys. J Med Primatol, 2010; 39:389–398.
39.
Gomez-IslaT, PriceJL, McKeelDWJr, et al.Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci, 1996; 16:4491–4500.
40.
KhanUA, LiuL, ProvenzanoFA, et al.Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease. Nat Neurosci, 2014; 17:304–311.
41.
WhitwellJL, PrzybelskiSA, WeigandSD, et al.3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. Brain, 2007; 130:1777–1786.
42.
YangX, YaoC, TianT, et al.A novel mechanism of memory loss in Alzheimer's disease mice via the degeneration of entorhinal-CA1 synapses. Mol Psychiatry, 2018; 23:199–210.
43.
Lafaille-MagnanME, PoirierJ, EtienneP, et al.Odor identification as a biomarker of preclinical AD in older adults at risk. Neurology, 2017; 89:327–335.
44.
TangX, QinY, WuJ, et al.Shape and diffusion tensor imaging based integrative analysis of the hippocampus and the amygdala in Alzheimer's disease. Magn Reson Imaging, 2016; 34:1087–1099.
45.
DaviesKG, BellBD, BushAJ, et al.Naming decline after left anterior temporal lobectomy correlates with pathological status of resected hippocampus. Epilepsia, 1998; 39:407–419.
46.
HamptonRR, BuckmasterCA, Anuszkiewicz-LundgrenD, et al.Method for making selective lesions of the hippocampus in macaque monkeys using NMDA and a longitudinal surgical approach. Hippocampus, 2004; 14:9–18.
47.
HorelJA. The neuroanatomy of amnesia. A critique of the hippocampal memory hypothesis. Brain, 1978; 101:403–445.
48.
RydenhagB, SilanderHC. Complications of epilepsy surgery after 654 procedures in Sweden, September 1990–1995: a multicenter study based on the Swedish National Epilepsy Surgery Register. Neurosurgery, 2001; 49:51–56; discussion 56–57.
49.
DaulatzaiMA. Olfactory dysfunction: its early temporal relationship and neural correlates in the pathogenesis of Alzheimer's disease. J Neural Transm (Vienna), 2015; 122:1475–1497.
50.
TzekovR, MullanM. Vision function abnormalities in Alzheimer disease. Surv Ophthalmol, 2014; 59:414–433.
51.
WoodwardRA, WeldKP. A comparison of ketamine, ketamine-acepromazine, and tiletamine-zolazepam on various hematologic parameters in rhesus monkeys (Macaca mulatta). Contemp Top Lab Anim Sci, 1997; 36:55–57.
52.
ChoudhurySR, HudryE, MaguireCA, et al.Viral vectors for therapy of neurologic diseases. Neuropharmacology, 2017; 120:63–80.
53.
JoshiCR, LabhasetwarV, GhorpadeA. Destination brain: the past, present, and future of therapeutic gene delivery. J Neuroimmune Pharmacol, 2017; 12:51–83.
54.
WildEJ, TabriziSJ. Therapies targeting DNA and RNA in Huntington's disease. Lancet Neurol, 2017; 16:837–847.
55.
HerzogCD, BishopKM, BrownL, et al.Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically active neurotrophic factor proteins for neurodegenerative diseases. Drug Deliv Transl Res, 2011; 1:361–382.
56.
HocquemillerM, GierschL, AudrainM, et al.Adeno-associated virus-based gene therapy for CNS diseases. Hum Gene Ther, 2016; 27:478–496.
57.
JansonC, McPheeS, BilaniukL, et al.Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther, 2002; 13:1391–1412.
58.
LauAA, HemsleyKM. Adeno-associated viral gene therapy for mucopolysaccharidoses exhibiting neurodegeneration. J Mol Med (Berl), 2017; 95:1043–1052.
59.
LeoneP, SheraD, McPheeSW, et al.Long-term follow-up after gene therapy for canavan disease. Sci Transl Med, 2012; 4:165ra163.
60.
SevinC, AubourgP, CartierN. Enzyme, cell and gene-based therapies for metachromatic leukodystrophy. J Inherit Metab Dis, 2007; 30:175–183.
61.
SmithBK, CollinsSW, ConlonTJ, et al.Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes. Hum Gene Ther, 2013; 24:630–640.
62.
TardieuM, ZerahM, HussonB, et al.Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a Phase I/II trial. Hum Gene Ther, 2014; 25:506–516.
63.
WirthB, BarkatsM, MartinatC, et al.Moving towards treatments for spinal muscular atrophy: hopes and limits. Expert Opin Emerg Drugs, 2015; 20:353–356.
64.
WorgallS, SondhiD, HackettNR, et al.Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther, 2008; 19:463–474.
GolebiowskiD, BradburyAM, KwonC-S, et al.AAV gene therapy strategies for lysosomal storage disorders with central nervous system involvement. In: BoX, VerhaagenJ, eds. Gene Delivery and Therapy for Neurological Disorders, Neuromethods. New York: Springer Science+Business Media, 2015:265–295.
67.
GriegerJC, SamulskiRJ. Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps. J Virol, 2005; 79:9933–9944.
68.
CearleyCN, VandenbergheLH, ParenteMK, et al.Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. Mol Ther, 2008; 16:1710–1718.
69.
AschauerDF, KreuzS, RumpelS. Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain. PLoS One, 2013; 8:e76310.
70.
LiuG, MartinsIH, ChioriniJA, et al.Adeno-associated virus type 4 (AAV4) targets ependyma and astrocytes in the subventricular zone and RMS. Gene Ther, 2005; 12:1503–1508.
71.
RosenbergJB, KaminskySM, AubourgP, et al.Gene therapy for metachromatic leukodystrophy. J Neurosci Res, 2016; 94:1169–1179.
72.
ThwaiteR, PagesG, ChillonM, et al.AAVrh.10 immunogenicity in mice and humans. Relevance of antibody cross-reactivity in human gene therapy. Gene Ther, 2015; 22:196–201.
73.
TardieuM, ZerahM, GougeonML, et al.Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled Phase 1/2 clinical trial. Lancet Neurol, 2017; 16:712–720.
74.
KaplittMG, FeiginA, TangC, et al.Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, Phase I trial. Lancet, 2007; 369:2097–2105.
75.
AubourgP. Gene therapy for leukodystrophy: progress, challenges and opportunities. Expert Opin Orphan Drugs, 2016; 4:359–367.
76.
SouweidaneMM, FraserJF, ArkinLM, et al.Gene therapy for late infantile neuronal ceroid lipofuscinosis: neurosurgical considerations. J Neurosurg Pediatr, 2010; 6:115–122.
77.
ColleMA, PiguetF, BertrandL, et al.Efficient intracerebral delivery of AAV5 vector encoding human ARSA in non-human primate. Hum Mol Genet, 2010; 19:147–158.
78.
HadaczekP, ForsayethJ, MirekH, et al.Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. Hum Gene Ther, 2009; 20:225–237.
79.
RosenbluthKH, EschermannJF, MittermeyerG, et al.Analysis of a simulation algorithm for direct brain drug delivery. NeuroImage, 2012; 59:2423–2429.
80.
VarenikaV, KellsAP, VallesF, et al.Controlled dissemination of AAV vectors in the primate brain. Prog Brain Res, 2009; 175:163–172.
81.
BucherT, DubreilL, ColleMA, et al.Intracisternal delivery of AAV9 results in oligodendrocyte and motor neuron transduction in the whole central nervous system of cats. Gene Ther, 2014; 21:522–528.
82.
DavidsonBL, SteinCS, HethJA, et al.Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci U S A, 2000; 97:3428–3432.
83.
GraySJ, Nagabhushan KalburgiS, McCownTJ, et al.Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther, 2013; 20:450–459.
84.
SamaranchL, SalegioEA, San SebastianW, et al.Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther, 2012; 23:382–389.
85.
HerenuCB, SonntagWE, MorelGR, et al.The ependymal route for insulin-like growth factor-1 gene therapy in the brain. Neuroscience, 2009; 163:442–447.
86.
PardridgeWM. CSF, blood–brain barrier, and brain drug delivery. Expert Opin Drug Deliv, 2016; 13:963–975.
87.
RegevL, EzrielevE, GershonE, et al.Genetic approach for intracerebroventricular delivery. Proc Natl Acad Sci U S A, 2010; 107:4424–4429.
88.
KatzML, CoatesJR, SibigtrothCM, et al.Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease). J Neurosci Res, 2014; 92:1591–1598.
89.
KatzML, TecedorL, ChenY, et al.AAV gene transfer delays disease onset in a TPP1-deficient canine model of the late infantile form of Batten disease. Sci Transl Med, 2015; 7:313ra180.
90.
PletichaJ, HeilmannLF, EvansCH, et al.Preclinical toxicity evaluation of AAV for pain: evidence from human AAV studies and from the pharmacology of analgesic drugs. Mol Pain, 2014; 10:54.
91.
BeutlerAS. AAV provides an alternative for gene therapy of the peripheral sensory nervous system. Mol Ther, 2010; 18:670–673.
92.
BevanAK, DuqueS, FoustKD, et al.Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther, 2011; 19:1971–1980.
93.
TowneC, SchneiderBL, KieranD, et al.Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6. Gene Ther, 2010; 17:141–146.
94.
MeyerK, FerraiuoloL, SchmelzerL, et al.Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose–response study in mice and nonhuman primates. Mol Ther, 2015; 23:477–487.
95.
HindererC, BellP, KatzN, et al.Evaluation of intrathecal routes of administration for adeno-associated viral vectors in large animals. Hum Gene Ther, 2018; 29:15–24.
96.
BelurLR, TemmeA, Podetz-PedersenKM, et al.Intranasal adeno-associated virus mediated gene delivery and expression of human iduronidase in the central nervous system: a noninvasive and effective approach for prevention of neurologic disease in mucopolysaccharidosis type I. Hum Gene Ther, 2017; 28:576–587.
97.
KochS, DonarskiN, GoetzeK, et al.Characterization of four lipoprotein classes in human cerebrospinal fluid. J Lipid Res, 2001; 42:1143–1151.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
